Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SD-06 is an ATP-competitive inhibitor of p38α MAPK (IC50 = 0.016 µM).1 It is selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all). SD-06 inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively). It decreases IL-1β-induced production of prostaglandin E2 (PGE2; Item No. 14010) in patient-derived rheumatoid arthritis synovial fibroblasts (RASFs; IC50 = 96.2 nM). SD-06 (30 mg/kg) reduces carrageenan-induced paw swelling and hyperalgesia in rats. It also reduces the incidence of arthritis in a mouse model of collagen-induced arthritis and protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis.
WARNING This product is not for human or veterinary use.
1. SD0006: A potent, selective and orally available inhibitor of p38 kinase. Pharmacology 84(1), 42-60 (2009).